243 related articles for article (PubMed ID: 35687691)
21. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
[TBL] [Abstract][Full Text] [Related]
22. Ectopic expression of SOX18 in Basal cell carcinoma negatively regulates tumour progression.
Villani R; Sim SL; Roy E; Wainwright B; Francois M; Khosrotehrani K
J Dermatol Sci; 2020 Jun; 98(3):179-185. PubMed ID: 32444239
[TBL] [Abstract][Full Text] [Related]
23. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
[TBL] [Abstract][Full Text] [Related]
24. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
25. Basal Cell Carcinoma in Gorlin's Patients: a Matter of Fibroblasts-Led Protumoral Microenvironment?
Gache Y; Brellier F; Rouanet S; Al-Qaraghuli S; Goncalves-Maia M; Burty-Valin E; Barnay S; Scarzello S; Ruat M; Sevenet N; Avril MF; Magnaldo T
PLoS One; 2015; 10(12):e0145369. PubMed ID: 26694869
[TBL] [Abstract][Full Text] [Related]
26. Basal cell carcinomas grown in nude mice produce and deposit fibronectin in the extracellular matrix.
Grimwood RE; Ferris CF; Nielsen LD; Huff JC; Clark RA
J Invest Dermatol; 1986 Jul; 87(1):42-6. PubMed ID: 3522753
[TBL] [Abstract][Full Text] [Related]
27. The Hedgehog pathway and its inhibitors: Emerging therapeutic approaches for basal cell carcinoma.
Jain R; Dubey SK; Singhvi G
Drug Discov Today; 2022 Apr; 27(4):1176-1183. PubMed ID: 34896624
[TBL] [Abstract][Full Text] [Related]
28. Advanced basal cell carcinoma: What dermatologists need to know about treatment.
Wilson M; Johnson RP; Senft SC; Pan EY; Krakowski AC
J Am Acad Dermatol; 2022 Jun; 86(6S):S14-S24. PubMed ID: 35577406
[TBL] [Abstract][Full Text] [Related]
29. The transcriptional landscape analysis of basal cell carcinomas reveals novel signalling pathways and actionable targets.
Litvinov IV; Xie P; Gunn S; Sasseville D; Lefrançois P
Life Sci Alliance; 2021 Jul; 4(7):. PubMed ID: 33972406
[TBL] [Abstract][Full Text] [Related]
30. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA; Pop OT; Ighilahriz M; Padioleau I; Rajabi F; Sharpe HJ; Poulalhon N; Dreno B; Khammari A; Delord M; Alberti A; Soufir N; Battistella M; Mourah S; Bouquet F; Savina A; Besse A; Mendez-Lopez M; Grange F; Monestier S; Mortier L; Meyer N; Dutriaux C; Robert C; Saiag P; Herms F; Lambert J; de Sauvage FJ; Dumaz N; Flatz L; Basset-Seguin N; Nikolaev SI
Clin Cancer Res; 2022 Apr; 28(7):1422-1432. PubMed ID: 35078858
[TBL] [Abstract][Full Text] [Related]
31. Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma.
Sternberg C; Gruber W; Eberl M; Tesanovic S; Stadler M; Elmer DP; Schlederer M; Grund S; Roos S; Wolff F; Kaur S; Mangelberger D; Lehrach H; Hache H; Wierling C; Laimer J; Lackner P; Wiederstein M; Kasper M; Risch A; Petzelbauer P; Moriggl R; Kenner L; Aberger F
Int J Cancer; 2018 Dec; 143(11):2943-2954. PubMed ID: 29987839
[TBL] [Abstract][Full Text] [Related]
32. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
33. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
Keating GM
Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
[TBL] [Abstract][Full Text] [Related]
34. Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma.
Sabu DM; Kroes J; Gilham C; Fleming A; Kelleher FC
Curr Probl Cancer; 2021 Dec; 45(6):100736. PubMed ID: 33894989
[TBL] [Abstract][Full Text] [Related]
35. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
Abidi A
Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
[TBL] [Abstract][Full Text] [Related]
37. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
[TBL] [Abstract][Full Text] [Related]
38. Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor-Resistant Basal Cell Carcinoma Cells via Targeting EGFR-MAPK-Akt and Hedgehog Signaling.
Dheeraj A; Rigby CM; O'Bryant CL; Agarwal C; Singh RP; Deep G; Agarwal R
Photochem Photobiol; 2017 Jul; 93(4):999-1007. PubMed ID: 28120452
[TBL] [Abstract][Full Text] [Related]
39. Peritumoral Clefting and Expression of MMP-2 and MMP-9 in Basal Cell Carcinoma of the Skin.
Manola I; Mataic A; Drvar DL; Pezelj I; Dzombeta TR; Kruslin B
In Vivo; 2020; 34(3):1271-1275. PubMed ID: 32354918
[TBL] [Abstract][Full Text] [Related]
40. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
